Cited by 25Bioinformatics and Genomic NetworksGene expression and cancer classificationCancer-related molecular mechanisms research

MORE: a multi-omics data-driven hypergraph integration network for biomedical data classification and biomarker identification

Open access
Wang, Yuhan, Wang, Zhikang, Yu, Xuan, Wang, Xiaoyu, Song, Jiangning, Yu, Dong-Jun, Ge, Fang·2024·Briefings in Bioinformatics

Abstract

High-throughput sequencing methods have brought about a huge change in omics-based biomedical study. Integrating various omics data is possibly useful for identifying some correlations across data modalities, thus improving our understanding of the underlying biological mechanisms and complexity. Nevertheless, most existing graph-based feature extraction methods overlook the complementary information and correlations across modalities. Moreover, these methods tend to treat the features of each omics modality equally, which contradicts current biological principles. To solve these challenges, we introduce a novel approach for integrating multi-omics data termed Multi-Omics hypeRgraph integration nEtwork (MORE). MORE initially constructs a comprehensive hyperedge group by extensively investigating the informative correlations within and across modalities. Subsequently, the multi-omics hypergraph encoding module is employed to learn the enriched omics-specific information. Afterward, the multi-omics self-attention mechanism is then utilized to adaptatively aggregate valuable correlations across modalities for representation learning and making the final prediction. We assess MORE’s performance on datasets characterized by message RNA (mRNA) expression, Deoxyribonucleic Acid (DNA) methylation, and microRNA (miRNA) expression for Alzheimer’s disease, invasive breast carcinoma, and glioblastoma. The results from three classification tasks highlight the competitive advantage of MORE in contrast with current state-of-the-art (SOTA) methods. Moreover, the results also show that MORE has the capability to identify a greater variety of disease-related biomarkers compared to existing methods, highlighting its advantages in biomedical data mining and interpretation. Overall, MORE can be investigated as a valuable tool for facilitating multi-omics analysis and novel biomarker discovery. Our code and data can be publicly accessed at https://github.com/Wangyuhanxx/MORE.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/bib/bbae658

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Multi-layer network construction and inference often require high-performance infrastructure, restricting participation to well-resourced institutions.

    “Multi-layer network construction and inference often require high-performance infrastructure, restricting participation to well-resourced institutions260.”

    From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [260]

    The Methods sections describe hypergraph construction and model optimization, but do not state that these require high-performance infrastructure. The Conclusion discusses limitations involving other data modalities, not access for less-resourced institutions. Searches for computational resources, hardware, and institutional access found no passage addressing the claim. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wang, Y., Wang, Z., Yu, X., Wang, X., Song, J., Yu, D.-J., & Ge, F.
Affiliations
  • Nanjing University of Science and Technology (CN)
  • Monash University (AU)
  • City University of Hong Kong (HK)
  • Nanjing University of Posts and Telecommunications (CN)
Corresponding author
  • Song, Jiangning
  • Yu, Dong-Jun
  • Ge, Fang
Venue
Briefings in Bioinformatics
Published
2024-11-22
Volume
26
Issue
1
ISSN
  • 1467-5463 (ISSN-L)
  • 1477-4054
OpenAlex
W4405563164
Cited by
25
References
71
Citations by year
2026: 13 · 2025: 12
FWCI
3.40
Type
journal article
Language
en
Open access
Locations
  • Briefings in Bioinformatics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CityU Scholars (submittedVersion, cc-by)
Funders
  • Natural Science Research Start-up Foundation of Recruiting Talents of Nanjing University of Posts and Telecommunications (NY223062)
  • Monash University
  • Natural Science Foundation of Jiangsu (BK20201304)
  • National Natural Science Foundation of China (62072243, 62372234)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
multi-omics integration, hypergraph neural networks, biomarker discovery, disease classification, self-attention, mRNA expression, DNA methylation, microRNA expression, Alzheimer's disease, invasive breast cancer, glioblastoma
MeSH terms
Multiomics, Algorithms, Alzheimer Disease, Breast Neoplasms, Glioblastoma, Humans, RNA, Messenger, Biomarkers, Tumor, Biomarkers, DNA Methylation, Computational Biology, Genomics, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review